MedTrace Logo

Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individuals

NCT00300742 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2017-07-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the feasibility of using topiramate to reduce binge eating and drinking episodes in alcohol dependent individuals with comorbid binge eating disorder.

Conditions

  • Alcohol Dependence
  • Binge Eating

Interventions

DRUG

Topiramate

Topiramate up to 300 mg per day.

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • Nassima Ait-Daoud, MD · University of Virginia, Department of Psychiatric Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2008-07-31
Completion
2008-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00300742 on ClinicalTrials.gov